Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on February 22, 2021. The filing discloses a material event regarding the regulatory status of the Company's New Drug Application (NDA) for SPN-812, a treatment for attention-deficit hyperactivity disorder (ADHD) in pediatric patients.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the classification of the NDA resubmission for SPN-812 by the U.S. Food and Drug Administration (FDA):
- The FDA designated the resubmission as a Class I resubmission.
- This classification assigns a review timeline of two months.
- A new Prescription Drug User Fee Act (PDUFA) target action date has been established for early April 2021.
Guidance, Outlook, and Risks
Outlook: The Company anticipates a regulatory decision from the FDA in early April 2021 based on the new PDUFA date.
Risks and Contingencies: The filing does not explicitly detail new risks beyond the inherent uncertainty of FDA review outcomes. The timeline is contingent upon the FDA's review process for the Class I resubmission.
Investor Verification Checklist
- Verify the exact PDUFA target action date for SPN-812 in early April 2021.
- Review the full text of the press release (Exhibit 99.1) for additional context on the Class I resubmission criteria.
- Monitor subsequent filings for the FDA's final decision on the NDA.
- Confirm the commercial launch timeline for SPN-812 pending FDA approval.